E-Clinical Solution Software Market is Expected to Be Biggest Emerging Market by 2020

| December 30, 2016

article image
The report presents a detailed analysis of the software systems designed specifically for managing and analyzing the vast volume of clinical data developed as a result of research activities undertaken by biotechnology, pharmaceutical, medical device companies. Owing to the rapidly increasing availability of highly advanced computer systems and reliable network of the Internet across the globe, the clinical trial industry has become highly connected and sophisticated. The mounting data from the rapidly increasing research activities and integration of computers in the healthcare field have given rise to the increased need for sophisticated e-clinical solution software across the globe.

Spotlight

BEC Chemicals Pvt. Ltd.

BEC Chemicals Pvt. Ltd specializes in manufacturing of Active pharmaceutical Ingredients (API’s) and Intermediates. The manufacturing unit in Roha (Raigad dist.) has been approved by Indian and European Drug Authority and is EU-GMP, WHO-GMP and State GMP certified. The company is ISO 9001:2008, 14001:2004, 18000:2007, OHSAS certified by SGS-UK. The manufacturing unit is a 100% Export Oriented Unit and is recognized as STAR EXPORT house by DGFT (INDIA). Recently we have been approved by USFDA.

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | April 3, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | April 3, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More
VIEWS AND ANALYSIS

New Dimensions of Clinical Trial Optimization

Article | April 3, 2020

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea of the optimized clinical trial has centered on optimal patient samples, target enrollment rates, and generally the most efficient uses of scarce resources in the form of patients. Yet anyone who has had to design and optimize a clinical trial, knows that trial optimization occurs within an ecosystem of choices; a series of choices that stretch from the time it takes to implement a clinical trial and submit clinical data for analysis, to general concerns about the cost and power of a clinical trial. A true clinical trial optimization process would try to unify a number of these choices into a single framework for trial optimization. The complexity of clinical trial optimization comes from the need to align priorities on the one hand, and to understand opportunities on the other. We know that at a very general level, clinical operations specialists benefit from simplicity in clinical trial design, and that commercial teams prefer shorter clinical trials to longer ones. We also know that the statistical design of a clinical trial can influence both simplicity and duration. Yet how many sponsors have their clinical operations and commercial teams, sit with their R&D teams to review various statistically nuanced design options? For many sponsors, the reason this process does not occur as often as it should, is because the nuanced statistical parameters of a clinical trial design are very difficult to communicate to non-statisticians. Yet a trial optimization tool like Solara, equipped with data visualizations and the ability to see tradeoffs intuitively, can overcome this challenge. The real challenge is often convincing the non-statistician that they have a stake in clinical trial design. Cytel recently had a client that thought it needed a sample size re-estimation design, because it had a very strict limit on the number of patients it could enroll. After a few hours of working with Solara, though, a statistician discovered that a much simpler Group Sequential Design would deliver comparable power using about the same number of patients. The gains from the more complex design were minimal from the optimization perspective, when understood as the eco-system of choices. Similarly, most commercial teams pressure their clinical trial designers to have the most accelerated clinical trial imaginable, but as we all know, the longer the clinical trial the more likely there will be a higher number of events that demonstrate the effectiveness of a new medicine. So commercialization teams have a stake in longer clinical trials, even when their rule of thumb is to shorten them. Therefore, it is absolutely essential to communicate the benefits of various statistical designs to multiple stakeholders in a way that makes tradeoffs clear. Aligning on priorities early during the clinical trial design process is essential to selecting the optimal clinical trial. Yet for this statisticians need to be equipped for both a strategic and communicative role in the R&D process.

Read More

Spotlight

BEC Chemicals Pvt. Ltd.

BEC Chemicals Pvt. Ltd specializes in manufacturing of Active pharmaceutical Ingredients (API’s) and Intermediates. The manufacturing unit in Roha (Raigad dist.) has been approved by Indian and European Drug Authority and is EU-GMP, WHO-GMP and State GMP certified. The company is ISO 9001:2008, 14001:2004, 18000:2007, OHSAS certified by SGS-UK. The manufacturing unit is a 100% Export Oriented Unit and is recognized as STAR EXPORT house by DGFT (INDIA). Recently we have been approved by USFDA.

Events